MedDataX Logo

Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy

NCT ID: NCT05187936

Last Updated: 2022-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hemophilia is a constitutional coagulation disorder responsible for a hemorrhagic phenotype in patients from an early age. Hemarthrosis is one of the most frequent complications in hemophiliacs and leads to the development of severe and early arthropathy, sometimes as early as childhood. To date, there is no curative treatment for these joint disorders and preventive treatments are insufficient to completely prevent joint degradation. Mesenchymal stem cells have been shown to be of therapeutic interest in the management of pathologies such as osteoarthritis and inflammatory arthritis through their anti-inflammatory, regenerative and anti-apoptotic effects. Hemophilic arthropathy is a separate condition at the border of these two diseases Our study aim to show pre-clinical interest of mesenchymal stem cell therapy in hemophilic arthropathy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pain and Joint Status With Psychosocial Factors in Patients With Hemophilia

NCT04715100

Hemophilia Arthropathy
UNKNOWN

COVID-19 Quarantine on Musculoskeletal Status in Hemophilia

NCT04491318

Hemophilia Arthropathy
COMPLETED

Central Sensitisation in Patients With Haemophilia and Degenerative Arthropathy

NCT07110675

Hemophilia
RECRUITING

Multidisciplinary Evaluation of Patients With Hemophilia

NCT02198430

Haemophilia
COMPLETED

Multidimensional Assessment of Chronic Pain in Severe Haemophilia A

NCT07096349

Hemophilia A Without Inhibitor
RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A Hemophilia B Arthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hemophilia A or B adult patient, with or without arthropathy
* Heathly control

Exclusion Criteria

* Antiinflammatory drug use
* immunosuppressive treatment or condition
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Montpellier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alexandre THERON

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Montpellier

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Uhmontpellier

Montpellier, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexandre THERON, MD

Role: CONTACT

[email protected]
467336519 ext. 33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexandre THERON, MD

Role: primary

[email protected]
467336519 ext. 33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RECHMPL21_0640

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins
NCT04206033 COMPLETED
Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia
NCT07099313 RECRUITING
Ultrasonography in Hemophilic Joint Disease and Serum Markers
NCT02634918 COMPLETED
Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
NCT00927667 COMPLETED PHASE4
Chronic Pain and Hemophilia
NCT05202951 RECRUITING
Conditioned Pain Modulation in Patients With Hemophilia
NCT06267209 RECRUITING
Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
NCT01571934 COMPLETED
Observational Study of Long-Term Joint Health Outcome in Hemophilia Patient
NCT04618237 UNKNOWN
Joint Outcome Study
NCT00207597 COMPLETED
Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia a Monitoring
NCT06369740 COMPLETED
Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)
NCT04731701 COMPLETED
Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia
NCT03914209 UNKNOWN
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia
NCT02866526 COMPLETED
Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia
NCT03299699 COMPLETED
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763 ACTIVE_NOT_RECRUITING
Platelet Function in Patients With Hemophilia A
NCT02093065 COMPLETED
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
NCT01496274 COMPLETED PHASE2/PHASE3
The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B
NCT03623295 COMPLETED
The Hemophilia Ultrasound Project
NCT02807753 TERMINATED
Musculoskeletal Function in Hemophilia
NCT00324493 UNKNOWN
Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia
NCT02108132 UNKNOWN PHASE1
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
NCT02453542 RECRUITING
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study
NCT06234813 COMPLETED NA
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
NCT04072237 COMPLETED PHASE1
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862 COMPLETED